The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
33 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,039,293 in first-year total cost, median $557,766.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OTC-C (56)]15
- Special Emphasis Panel[ZRG1 OTC-J (55)]10
- Special Emphasis Panel[ZRG1 OTC-N (55)]7
- Radiation Therapeutics and Biology Study Section[RTB]1
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO3
- JOHNS HOPKINS UNIVERSITY2
- SLOAN-KETTERING INST CAN RESEARCH2
- UNIV OF MASSACHUSETTS MED SCH WORCESTER2
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Leveraging canine spontaneous cancer to optimize the power of blood biopsy1R01CA255319-01 | KARLSSON, ELINORLONDON, CHERYL A | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $645,307 | ZRG1 |
| 2021 | Radiogenomic Credentialing of Head and Neck Cancer Models1R01CA243456-01A1 | SESHADRI, MUKUND | ROSWELL PARK CANCER INSTITUTE CORP, NY | $623,637 | ZRG1 |
| 2021 | Modeling myelodysplasia1R01CA253981-01A1 | GRIMES, H. LEIGHTONHALENE, STEPHANIE | CINCINNATI CHILDRENS HOSP MED CTR, OH | $614,181 | ZRG1 |
| 2021 | Visualizing tumor heterogeneity in an immune intact and autochthonous mouse model of breast cancer1R01CA255372-01 | SNYDER, JOSHUA CLAIR | DUKE UNIVERSITY, NC | $365,458 | ZRG1 |
| 2020 | Mouse models of Kras-mutant colorectal cancer1R01CA246653-01A1 | HAIGIS, KEVIN | DANA-FARBER CANCER INST, MA | $646,021 | ZRG1 |
| 2020 | Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics1R01CA244327-01A1 | BOURNAZOS, STYLIANOS | ROCKEFELLER UNIVERSITY, NY | $633,648 | ZRG1 |
| 2020 | Development of Advanced Preclinical Models for Pediatric Solid Tumors1R01CA243555-01A1 | HAUSSLER, DAVID HSWEET-CORDERO, ERIC ALEJANDRO | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $616,057 | ZRG1 |
| 2020 | Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model1R01CA248277-01 | FIELDS, RYAN CFLAVELL, RICHARD A | WASHINGTON UNIVERSITY, MO | $612,841 | ZRG1 |
| 2020 | Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient1R37CA248289-01 | SMITH, JESSE JOSHUA | SLOAN-KETTERING INST CAN RESEARCH, NY | $611,246 | ZRG1 |
| 2020 | Rapid ex vivo biosensor cultures to assess dependencies in gastroesophageal cancer1R01CA248280-01 | BOEHM, JESSE SAMUEL | BROAD INSTITUTE, INC., MA | $566,213 | ZRG1 |
| 2020 | Developing translationally-relevant genetically engineered mouse models of lung adenocarcinoma for investigations in cancer immunology1R01CA237037-01A1 | JOSHI, NIKHIL | YALE UNIVERSITY, CT | $557,766 | ZRG1 |
| 2020 | Improving hepatocellular carcinoma mouse modeling by understanding the malignant potential and biology of liver cell subpopulations1R01CA251928-01 | ZHU, HAO | UT SOUTHWESTERN MEDICAL CENTER, TX | $542,616 | ZRG1 |
| 2020 | Modeling the Glioblastoma Microenvironment to Uncover Progression Mechanisms and Therapeutic Targets1R01CA247905-01 | BRAT, DANIEL J | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $522,787 | ZRG1 |
| 2020 | Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies1R01CA233944-01A1 | LOWE, SCOTT W. | SLOAN-KETTERING INST CAN RESEARCH, NY | $488,090 | ZRG1 |
| 2020 | A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma1R01CA247970-01 | LANG, FREDERICK F | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $454,473 | ZRG1 |
| 2020 | Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects1R01CA246722-01A1 | GUPTA, NALINROSI, SUSANNA | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $370,054 | RTB |
| 2020 | Development of novel metastatic mouse models that recapitulate the major immune contexts of human colon cancer1R01CA233983-01A1 | JACKS, TYLER E. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $332,226 | ZRG1 |
| 2019 | In Vivo Base Editing for Precision Oncology Models1R01CA229773-01A1 | DOW, LUKAS EDWARD | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $646,960 | ZRG1 |
| 2019 | Mouse modeling of HPV infection1R01CA233486-01 | HUNG, CHIEN-FURODEN, RICHARD BRUCE | JOHNS HOPKINS UNIVERSITY, MD | $596,869 | ZRG1 |
| 2019 | Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy1R01CA237067-01 | WU, TZYY-CHOOU | JOHNS HOPKINS UNIVERSITY, MD | $596,869 | ZRG1 |
| 2019 | Polymerase-mediated ultramutagenesis and carcinogenesis in mice1R01CA237405-01 | CASTRILLON, DIEGO H | UT SOUTHWESTERN MEDICAL CENTER, TX | $552,634 | ZRG1 |
| 2019 | Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors1R01CA234128-01 | KARIN, MICHAEL | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $550,740 | ZRG1 |
| 2019 | Modeling Factors Associated with Risk of High-Grade Serous Carcinoma in Mice1R01CA226756-01A1 | CHO, KATHLEEN R. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $533,016 | ZRG1 |
| 2019 | Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia1R37CA234021-01A1 | PADRON, ERIC | H. LEE MOFFITT CANCER CTR & RES INST, FL | $514,636 | ZRG1 |
| 2019 | Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)1R01CA222148-01A1 | LIU, XUEFENG | GEORGETOWN UNIVERSITY, DC | $493,219 | ZRG1 |
| 2019 | Definition of Immune Infiltrate Phenotype and DNA Damage Response Deficits Across Diverse Murine Mammary Carcinomas1R01CA239235-01 | BARCELLOS-HOFF, MARY HELEN | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $486,710 | ZRG1 |
| 2019 | Credentialing a Genetically Engineered Clinically-Relevant Mouse Model of Multiple Myeloma1R01CA234181-01 | CHESI, MARTA | MAYO CLINIC ARIZONA, AZ | $379,725 | ZRG1 |
| 2018 | Transforming family dogs into a powerful and accessible model for human cancer1R37CA218570-01A1 | KARLSSON, ELINOR | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $687,174 | ZRG1 |
| 2018 | Advancing treatment outcomes in malignant glioma by integrating immunotherapy and standard of care using genetically engineered mice that recapitulate molecular feature of human glioma1R01CA229784-01 | BOUSSIOTIS, VASSILIKI ACHAREST, ALAIN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $667,694 | ZRG1 |
| 2018 | Translational Applications in an Animal Model of Pancreatic Cystic Neoplasm and Cancer1R01CA218004-01A1 | MAITRA, ANIRBAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $597,598 | ZRG1 |
| 2018 | Development and Application of a Porcine Model of Pancreatic Cancer1R01CA222907-01A1 | CARLSON, MARK A | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $568,591 | ZRG1 |
| 2018 | Mammalian models for integrated metabolic and molecular profiling of malignant glioma1R01CA227089-01A1 | GRAEBER, THOMAS GNATHANSON, DAVID A. | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $553,813 | ZRG1 |
| 2018 | Enhancing the dog as a model for human cancers: from genome sequence towards clinical trials.1R01CA225755-01A1 | LINDBLAD-TOH, KERSTIN | UPPSALA UNIVERSITY | $410,424 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.